Organogenesis Inc.

organogenesis.com

Organogenesis Inc. is a leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

EMERGENCE THERAPEUTICS LICENSES SYNAFFIX ADC TECHNOLOGY PLATFORM IN $360M DEAL

Synaffix | September 07, 2022

news image

Synaffix B.V. and Emergence Therapeutics AG announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix's proprietary antibody drug conjugate technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload. Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on...

Read More

Medical

FELIX BIOTECHNOLOGY ANNOUNCES INITIATION OF CYPHY PHASE 1/2 STUDY AT YALE FOR LEAD ASSET

Felix Biotechnology | January 08, 2021

news image

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and...

Read More

Medical

PFIZER COMPLETES ACQUISITION OF REVIRAL

Pfizer | June 10, 2022

news image

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell. Sisunat...

Read More

CYTOGENETICS MARKET IS NEW BUSINESS OPPORTUNITIES AND INVESTMENT RESEARCH REPORT BY 2026

Publicist360 | April 09, 2020

news image

Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...

Read More
news image

Industrial Impact

EMERGENCE THERAPEUTICS LICENSES SYNAFFIX ADC TECHNOLOGY PLATFORM IN $360M DEAL

Synaffix | September 07, 2022

Synaffix B.V. and Emergence Therapeutics AG announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix's proprietary antibody drug conjugate technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload. Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on...

Read More
news image

Medical

FELIX BIOTECHNOLOGY ANNOUNCES INITIATION OF CYPHY PHASE 1/2 STUDY AT YALE FOR LEAD ASSET

Felix Biotechnology | January 08, 2021

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and...

Read More
news image

Medical

PFIZER COMPLETES ACQUISITION OF REVIRAL

Pfizer | June 10, 2022

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell. Sisunat...

Read More
news image

CYTOGENETICS MARKET IS NEW BUSINESS OPPORTUNITIES AND INVESTMENT RESEARCH REPORT BY 2026

Publicist360 | April 09, 2020

Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us